Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-10-26
DOI
10.1111/joim.13581
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
- (2021) Maximilian Stahl et al. Blood Advances
- Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
- (2021) Matteo Piccini et al. Journal of Clinical Medicine
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
- (2021) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
- (2020) Yu-Wen Wang et al. ANNALS OF HEMATOLOGY
- Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression
- (2020) Brenda J Chyla et al. BLOOD
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
- (2020) Jan Philipp Bewersdorf et al. HAEMATOLOGICA
- Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
- (2020) Seth E Karol et al. LANCET ONCOLOGY
- How I Treat Relapsed or Refractory AML
- (2020) Susan E DeWolf et al. BLOOD
- Treatment of Relapsed Acute Myeloid Leukemia
- (2020) Felicitas Thol et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party ( ALWP ) of the European group for blood and marrow transplantation (EBMT)
- (2020) Monica Poiani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2019) Ibrahim Aldoss et al. AMERICAN JOURNAL OF HEMATOLOGY
- Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study
- (2019) Sijian Yu et al. LEUKEMIA
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
- (2018) Nimitha R Mathew et al. NATURE MEDICINE
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- The role of second transplants for leukemia
- (2016) Daniel Weisdorf BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat refractory and early relapsed acute myeloid leukemia
- (2015) F. Thol et al. BLOOD
- Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
- (2013) Maximilian Christopeit et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started